keyword
MENU ▼
Read by QxMD icon Read
search

Gi-net

keyword
https://www.readbyqxmd.com/read/29794066/phase-ii-study-of-everolimus-and-octreotide-lar-in-patients-with-nonfunctioning-gastrointestinal-neuroendocrine-tumors-the-getne1003_everlar-study
#1
Jaume Capdevila, Alexandre Teulé, Jorge Barriuso, Daniel Castellano, Carlos Lopez, Jose Luis Manzano, Vicente Alonso, Rocío García-Carbonero, Emma Dotor, Ignacio Matos, Ana Custodio, Oriol Casanovas, Ramon Salazar
BACKGROUND: Antitumor activity of the combination of somatostatin analogues (SSAs) and the mammalian target of rapamycin (mTOR) inhibitor everolimus in patients with neuroendocrine tumors (NETs) has been reported but not confirmed in prospective trials. MATERIALS AND METHODS: This prospective, multicenter, single-arm phase II EVERLAR study evaluated everolimus 10 mg/day and the SSA octreotide 30 mg every 28 days in patients with advanced nonfunctioning well-differentiated gastrointestinal NETs (GI-NETs) that progressed in the last 12 months (ClinicalTrials...
May 23, 2018: Oncologist
https://www.readbyqxmd.com/read/29746336/resection-of-the-primary-gastrointestinal-neuroendocrine-tumor-improves-survival-with-or-without-liver-treatment
#2
Aaron Lewis, Mustafa Raoof, Philip H G Ituarte, John Williams, Laleh Melstrom, Daneng Li, Byrne Lee, Gagandeep Singh
OBJECTIVE: The aim of this study was to determine outcomes of primary tumor resection in metastatic neuroendocrine tumors across all primary tumor sites. BACKGROUND: Primary tumor resection (PTR) may offer a survival benefit in metastatic gastrointestinal neuroendocrine tumors (GI-NETs); however, few studies have examined the effect of primary site and grade on resection and survival. METHODS: This is a retrospective study of patients with metastatic GI-NETs at presentation between 2005 and 2011 using the California Cancer Registry (CCR) dataset merged with California Office of Statewide Health Planning and Development (OSHPD) inpatient longitudinal database...
May 9, 2018: Annals of Surgery
https://www.readbyqxmd.com/read/29741466/first-line-systemic-treatment-adherence-healthcare-resource-utilization-and-costs-in-patients-with-gastrointestinal-neuroendocrine-tumors-gi-nets-in-the-usa
#3
Michael S Broder, Beilei Cai, Eunice Chang, Tingjian Yan, Al B Benson
AIMS: To assess treatment adherence, healthcare resource utilization, and costs in GI NET patients initiating pharmacologic treatments in the US. METHODS: In 2 US commercial claims databases, patients ≥18 years with ≥1 inpatient or ≥2 outpatient GI NET claims within 12 months were identified. The first claim for pharmacologic treatments (e.g., somatostatin analogues [SSAs], cytotoxic chemotherapy [CC], targeted therapy [TT]) following diagnosis, between 7/1/2009-12/31/2014, was defined as the index date...
May 9, 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29662560/impact-of-68-ga-dota-peptide-pet-ct-on-the-management-of-gastrointestinal-neuroendocrine-tumour-gi-net-malaysian-national-referral-centre-experience
#4
Teik Hin Tan, Ching Yeen Boey, Boon Nang Lee
Purpose: The National Cancer Institute is the only referral centre in Malaysia that provides 68 Ga-DOTA-peptide imaging. The purpose of this study is to determine the impact of 68 Ga-DOTA-peptide PET/CT on the management of gastrointestinal neuroendocrine tumours (GI-NET). Materials and Methods: A cross-sectional study was performed to review the impact of 68 Ga-DOTA-peptide (68 Ga-DOTATATE or 68 Ga-DOTATOC) PET/CT on patients with biopsy-proven GI-NET between January 2011 and December 2015...
April 2018: Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29213282/determination-of-mammalian-target-of-rapamycin-hyperactivation-as-prognostic-factor-in-well-differentiated-neuroendocrine-tumors
#5
G Lamberti, C Ceccarelli, N Brighi, I Maggio, D Santini, C Mosconi, C Ricci, G Biasco, D Campana
Purpose: To evaluate the role of the activation of mTOR (phosphorylated mTOR, p-mTOR) and the expression SSTR2A and IGF-1R as prognostic factor in well-differentiated neuroendocrine tumors. Methods: A retrospective study was conducted on data from patients with diagnosis of neuroendocrine tumor originated from pancreas (pNET) or gastrointestinal tract (stomach, appendix, and ileus; GI-NET) made between January 2003 and December 2004 and followed up at our institution...
2017: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/29194046/updates-on-the-biology-of-serotonin-and-tryptophan-hydroxylase
#6
Tara Swami, H Christian Weber
PURPOSE OF REVIEW: To summarize the most recent findings relevant to the biology of serotonin (5-hydroxytryptamine; 5-HT) and the enzyme tryptophan hydroxylase (TPH) in human gastrointestinal disease. RECENT FINDINGS: Serotonin is synthesized in the central nervous system (CNS) and the gastrointestinal tract where it is secreted from enteroendocrine cells. Its biosynthesis is regulated by two isoforms of the enzyme TPH of which TPH1 is localized predominantly in gastrointestinal enteroendocrine cells...
February 2018: Current Opinion in Endocrinology, Diabetes, and Obesity
https://www.readbyqxmd.com/read/29142475/predictive-factors-associated-with-carcinoid-syndrome-in-patients-with-gastrointestinal-neuroendocrine-tumors
#7
Beilei Cai, Michael S Broder, Eunice Chang, Tingjian Yan, David C Metz
AIM: To discover unknown factors associated with carcinoid syndrome (CS) with the goal of earlier diagnosis of CS. METHODS: In this retrospective case-control study using United States administrative claims, patients (≥ 18 years) newly-diagnosed with gastrointestinal neuroendocrine tumors (GI NETs) without CS (controls) were exactly matched to patients with CS (cases) based on NET diagnosis date at a 3-to-1 ratio. Study index date was first CS diagnosis (controls: same distance from NET diagnosis as cases)...
October 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29081664/impact-of-prior-therapies-on-everolimus-activity-an-exploratory-analysis-of-radiant-4
#8
Roberto Buzzoni, Carlo Carnaghi, Jonathan Strosberg, Nicola Fazio, Simron Singh, Fabian Herbst, Antonia Ridolfi, Marianne E Pavel, Edward M Wolin, Juan W Valle, Do-Youn Oh, James C Yao, Rodney Pommier
BACKGROUND: Recently, everolimus was shown to improve median progression-free survival (PFS) by 7.1 months in patients with advanced, progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) tract compared with placebo (HR, 0.48; 95% CI, 0.35-0.67; P <0.00001) in the Phase III, RADIANT-4 study. This post hoc analysis evaluates the impact of prior therapies (somatostatin analogs [SSA], chemotherapy, and radiotherapy) on everolimus activity...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28970728/real-world-treatment-patterns-of-gastrointestinal-neuroendocrine-tumors-a-claims-database-analysis
#9
Al B Benson, Michael S Broder, Beilei Cai, Eunice Chang, Maureen P Neary, Elya Papoyan
AIM: To describe real-world treatment patterns of gastrointestinal neuroendocrine tumors (GI NET). METHODS: In this retrospective cohort study, we used 2009-2014 data from 2 United States commercial claims databases to examine newly pharmacologically treated patients using tabular and graphical techniques. Treatments included somatostatin analogues (SSA), cytotoxic chemotherapy (CC), targeted therapy (TT), interferon (IF) and combinations. We identified patients at least 18 years of age, with ≥ 1 inpatient or ≥ 2 outpatient claims for GI NET who initiated pharmacologic treatment from 7/1/09-6/30/14...
September 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28710883/an-atypical-type-i-gastric-neuroendocrine-tumor
#10
REVIEW
Andrada-Viorela Gheorghe, Mihai Rimbas, Octav Ginghina, Andrada Spanu, Theodor Alexandru Voiosu
BACKGROUND: Gastric neuroendocrine tumors (GI-NETs) are rare lesions, usually discovered incidentally during endoscopy. Based on their pathology, there are 4 types of GI-NETs. Type I are multiple small polypoid lesions with central ulceration located in the gastric body or the fundus, associated with atrophic gastritis usually noninvasive and very rarely metastatic. We report on a rare case of a gastric NET arising from the muscularis propria layer of the pyloric ring. CASE REPORT: We present the case of a 65-year old woman with a history of alcoholic cirrhosis, investigated for melena...
December 1, 2017: Romanian Journal of Internal Medicine, Revue Roumaine de Médecine Interne
https://www.readbyqxmd.com/read/28704096/epidemiology-of-gastrointestinal-neuroendocrine-tumors-in-a-u-s-commercially-insured-population
#11
Michael S Broder, Beilei Cai, Eunice Chang, Maureen P Neary
OBJECTIVE: To estimate incidence and prevalence of gastrointestinal neuroendocrine tumors (GI NETs) in U.S. commercially insured patients. METHODS: This was a retrospective, cross-sectional study using 2009 to 2014 data from MarketScan and PharMetrics commercial claims databases. Patients were 18 to 64 years old, and had 1 inpatient or 2 outpatient claims with GI NET, identified by International Classification of Diseases, 9th Revision, Clinical Modification codes...
October 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28608155/pathophysiology-of-gastric-nets-role-of-gastrin-and-menin
#12
REVIEW
Sinju Sundaresan, Anthony J Kang, Juanita L Merchant
PURPOSE OF REVIEW: Neuroendocrine tumors (NETs) were initially identified as a separate entity in the early 1900s as a unique malignancy that secretes bioactive amines. GI-NETs are the most frequent type and represent a unique subset of NETs, because at least 75% of these tumors represent gastrin stimulation of the enterochromaffin-like cell located in the body of the stomach. The purpose of this review is to understand the specific role of gastrin in the generation of Gastric NETs (G-NETs)...
July 2017: Current Gastroenterology Reports
https://www.readbyqxmd.com/read/28423496/mtor-inhibitors-activate-perk-signaling-and-favor-viability-of-gastrointestinal-neuroendocrine-cell-lines
#13
Patricia Freis, Julien Bollard, Justine Lebeau, Patrick Massoma, Joëlle Fauvre, Cécile Vercherat, Thomas Walter, Serge Manié, Colette Roche, Jean-Yves Scoazec, Carole Ferraro-Peyret
mTOR and Unfolded Protein Response (UPR) are two signaling pathways frequently activated in cancer cells. The mTOR pathway has been shown to be up-regulated in most gastroenteropancreatic neuroendocrine tumors. In contrast, little is known about the UPR status in neoplastic neuroendocrine cells. However, these hormone-producing cells are likely to present distinctive adaptations of this pathway, as other secretory cells. We therefore analyzed the status of the three axes of UPR and their relation to mTOR pathway in two gastrointestinal neuroendocrine tumors (GI-NET) cell lines STC-1 and GluTag...
March 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28283864/lower-gastrointestinal-neuroendocrine-neoplasms-associated-with-hereditary-cancer-syndromes-a-case-series
#14
Trilokesh D Kidambi, Christina Pedley, Amie Blanco, Emily K Bergsland, Jonathan P Terdiman
Lower gastrointestinal (GI) neuroendocrine neoplasms (NENs) of the colon and rectum are uncommon and not traditionally associated with hereditary GI cancer syndromes. However, with widespread implementation of colorectal cancer screening programs, lower GI NENs are being identified with increasing frequency. We report the first case series of six patients with lower GI NENs who were diagnosed with hereditary GI cancer syndromes by germline testing. Two patients presented with poorly differentiated rectal neuroendocrine carcinoma (NECs) with colonic polyposis and were found to have Familial Adenomatous Polyposis and MYH-Associated Polyposis, respectively...
October 2017: Familial Cancer
https://www.readbyqxmd.com/read/27981858/budget-impact-of-everolimus-for-the-treatment-of-progressive-well-differentiated-non-functional-neuroendocrine-tumors-of-gastrointestinal-or-lung-origin-that-are-advanced-or-metastatic
#15
Darya B Rose, Dave Nellesen, Maureen P Neary, Beilei Cai
BACKGROUND: Advanced neuroendocrine tumors (NETs) are a rare malignancy with considerable need for effective therapies. Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) in 2016 for treatment of adults with progressive, well-differentiated, non-functional NETs of gastrointestinal (GI) or lung origin that are unresectable, locally advanced, or metastatic. OBJECTIVE: To assess the 3-year budget impact for a typical US health plan following availability of everolimus for treatment of GI and lung NETs...
April 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/27942928/efficacy-and-safety-of-everolimus-and-sunitinib-in-patients-with-gastroenteropancreatic-neuroendocrine-tumor
#16
Changhoon Yoo, Hyungwoo Cho, Min Jeong Song, Seung-Mo Hong, Kyu-Pyo Kim, Heung-Moon Chang, Heejung Chae, Tae Won Kim, Yong Sang Hong, Min-Hee Ryu, Yoon-Koo Kang, Song Cheol Kim, Baek-Yeol Ryoo
PURPOSE: Efficacy of targeted agents, such as everolimus and sunitinib, has been demonstrated in prospective trials on patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Considering the heterogeneous clinicopathological characteristics of neuroendocrine tumors (NETs), evaluation of treatment outcomes in a real-world setting is necessary. METHODS: Clinical records of 44 patients with GEP-NET who were treated with everolimus or sunitinib between March 2007 and October 2014 were retrospectively reviewed...
January 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/27570419/management-of-gastric-and-duodenal-neuroendocrine-tumors
#17
REVIEW
Yuichi Sato, Satoru Hashimoto, Ken-Ichi Mizuno, Manabu Takeuchi, Shuji Terai
Gastrointestinal neuroendocrine tumors (GI-NETs) are rare neoplasms, like all NETs. However, the incidence of GI-NETS has been increasing in recent years. Gastric NETs (G-NETs) and duodenal NETs (D-NETs) are the common types of upper GI-NETs based on tumor location. G-NETs are classified into three distinct subgroups: type I, II, and III. Type I G-NETs, which are the most common subtype (70%-80% of all G-NETs), are associated with chronic atrophic gastritis, including autoimmune gastritis and Helicobacter pylori associated atrophic gastritis...
August 14, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27330538/liver-metastasis-of-gastrointestinal-neuroendocrine-tumors-a-single-center-experience
#18
Bita Geramizadeh, Ali Kashkooe, Seyed Ali Malekhosseini
BACKGROUND: Gastrointestinal neuroendocrine tumors (GI-NETs) are potentially malignant tumors, and their most common location of metastasis is the liver. OBJECTIVES: In this report, we will describe our experience with some clinical and pathologic findings of hepatic metastasis in a group of cases of GI-NETs at the largest referral center of GI and liver diseases in south Iran. MATERIALS AND METHODS: In this four-year study (2011 - 2014), all GI and liver NETs were extracted from the pathology files of hospitals affiliated with Shiraz University of Medical Sciences...
May 2016: Hepatitis Monthly
https://www.readbyqxmd.com/read/27236421/diagnosis-and-management-of-gastrointestinal-neuroendocrine-tumors-an-evidence-based-canadian-consensus
#19
REVIEW
Simron Singh, Sylvia L Asa, Chris Dey, Hagen Kennecke, David Laidley, Calvin Law, Timothy Asmis, David Chan, Shereen Ezzat, Rachel Goodwin, Ozgur Mete, Janice Pasieka, Juan Rivera, Ralph Wong, Eva Segelov, Daniel Rayson
The majority of neuroendocrine tumors originate in the digestive system and incidence is increasing within Canada and globally. Due to rapidly evolving evidence related to diagnosis and clinical management, updated guidance on the diagnosis and treatment of gastrointestinal neuroendocrine tumors (GI-NETs) are of clinical importance. Well-differentiated GI-NETs may exhibit indolent clinical behavior and are often metastatic at diagnosis. Some NET patients will develop secretory disease requiring symptom control to optimize quality of life and clinical outcomes...
June 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/27082572/effectiveness-of-endoscopic-treatment-for-gastrointestinal-neuroendocrine-tumors-a-retrospective-study
#20
Weili Sun, Siyuan Wu, Xiao Han, Chuanhua Yang
Several recent studies have explored efficacy and safety of different endoscopic treatments for gastrointestinal neuroendocrine tumors (GI-NETs). However, there is no definitive consensus regarding the best endoscopic approach for GI-NETs treatment. Therefore, the present study was conducted to investigate the application of various endoscopic techniques for the treatment of GI-NETs according to the previous conclusions and to summarize the optimal endoscopic modalities for GI-NETs. Ninety-eight patients with 100 GI-NETs removed by endoscopic therapies were reviewed...
April 2016: Medicine (Baltimore)
keyword
keyword
5009
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"